- Dimerix (DXB) has received Australian ethics approval for its phase three COVID-19 study, dubbed CLARITY 2.0
- This approval is from the Research Ethics and Governance Office Ethics Committee and is for trialing DMX-200 in patients with COVID-19 respiratory complications
- The study approval comes as COVID-19 case numbers and hospitalisations rise significantly across Australia, which may influence recruitment rates
- Dimerix is expecting to recruit patient across Queensland, Victoria, New South Wales in January
- On the market, Dimerix is up 4.35 per cent and trading at 24 cents per share
Dimerix (DXB) has received Australian ethics approval for its phase three COVID-19 study, dubbed CLARITY 2.0
This approval is from the Research Ethics and Governance Office Ethics Committee and is for trialing DMX-200 in patients with COVID-19 respiratory complications.
Dimerix is expecting to recruit patient across Queensland, Victoria, New South Wales in January.
The study approval comes as COVID-19 case numbers and hospitalisations rise significantly across Australia, which may influence recruitment rates.
There is an estimated 33,140 active COVID-19 cases in Australia and approximately 850 patients currently hospitalised.
CLAITY 2.0 is already approved and open for recruitment and is expected to recruit around 600 patients across both India and Australia.
Antiviral medications are normally effective at preventing damage caused by a virus when taken three to five days of infection.
In contrast, DMX-200 does not rely on early inhibition of viral replication but aims to prevent the damaging immune response and lung flooding regardless of vaccination or antiviral treatment.
This also means that DMX-200 may be beneficial for patients with a wide range of respiratory diseases in addition to the various COVID-19 variants.
On the market, Dimerix was up 4.35 per cent and is trading at 24 cents per share at 12:27 pm AEDT.